Data from Hierarchical Organization of Prostate Cancer Cells in Xenograft Tumors: The CD44<sup>+</sup>α2β1<sup>+</sup> Cell Population Is Enriched in Tumor-Initiating Cells

Prostate cancer cells are heterogeneous in their tumorigenicity. For example, the side population cells isolated from LAPC9 xenografts are 100 to 1,000 times more tumorigenic than the corresponding non–side population cells. Highly purified CD44⁺ prostate cancer cells from several xenografts are also enriched in prostate cancer stem/progenitor cells. Because the CD44⁺ prostate cancer cell population is still heterogeneous, we wonder whether we could further enrich for tumorigenic prostate cancer cells in this population using other markers. Integrin α2β1 has been proposed to mark a population of normal human prostate stem cells. Therefore, we first asked whether the α2β1^+/hi cells in prostate tumors might also represent prostate cancer stem cells. Highly purified (≥98%) α2β1^+/hi cells from three human xenograft tumors, Du145, LAPC4, and LAPC9, show higher clonal and clonogenic potential than the α2β1^−/lo cells in vitro. However, when injected into the nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse prostate or s.c., the α2β1^+/hi prostate cancer cells are no more tumorigenic than the α2β1^−/lo cells. Immunofluorescence studies reveal that CD44 and α2β1 identify an overlapping and inclusive population of prostate cancer cells in that ∼70% of α2β1^+/hi cells are CD44⁺ and 20% to 30% of CD44⁺ cells are distributed in the α2β1^−/lo cell population. Subsequently, we sorted out CD44⁺α2β1^+/hi, CD44⁺α2β1^−/lo, CD44⁻α2β1^+/hi, and CD44⁻α2β1^−/lo cells from LAPC9 tumors and carried out tumorigenicity experiments. The results revealed a hierarchy in tumorigenic potential in the order of CD44⁺α2β1^+/hi ≈ CD44⁺α2β1^−/lo > CD44⁻α2β1^+/hi ≫ CD44⁻α2β1^−/lo. These observations together suggest that prostate cancer cells are organized as a hierarchy. [Cancer Res 2007;67(14):6796–805]